These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27453546)

  • 1. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Pham LV; Pedersen MS; Fahnøe U; Fernandez-Antunez C; Humes D; Schønning K; Ramirez S; Bukh J
    Gut; 2022 Mar; 71(3):627-642. PubMed ID: 33833066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S
    Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
    Tao W; Gan T; Lu J; Zhong J
    Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
    Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
    Xu S; Doehle B; Rajyaguru S; Han B; Barauskas O; Feng J; Perry J; Dvory-Sobol H; Svarovskaia ES; Miller MD; Mo H
    Antivir Ther; 2017; 22(7):587-597. PubMed ID: 28248189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.
    Gottwein JM; Scheel TK; Hoegh AM; Lademann JB; Eugen-Olsen J; Lisby G; Bukh J
    Gastroenterology; 2007 Nov; 133(5):1614-26. PubMed ID: 17983807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
    Ramirez S; Li YP; Jensen SB; Pedersen J; Gottwein JM; Bukh J
    Hepatology; 2014 Feb; 59(2):395-407. PubMed ID: 23913364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.
    Chen M; Xu Y; Li N; Yin P; Zhou Q; Feng S; Wu T; Wei L; Wang H; Fu Y; Li YP
    J Gen Virol; 2021 Dec; 102(12):. PubMed ID: 34949310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
    Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
    Younas S; Sumrin A; Hussain N; Bilal M
    J Appl Microbiol; 2022 Nov; 133(5):2826-2834. PubMed ID: 35916643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
    Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
    J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
    Pham LV; Ramirez S; Carlsen THR; Li YP; Gottwein JM; Bukh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
    PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.
    Gallego I; Sheldon J; Moreno E; Gregori J; Quer J; Esteban JI; Rice CM; Domingo E; Perales C
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3786-93. PubMed ID: 27067341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.